Increased programmed death ligand (PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) expression is associated with metastasis and poor prognosis in malignant canine mammary gland tumours.
CTLA-4
Canine
Mammary tumours
Metastasis
PD-L1
Prognosis
Journal
Veterinary immunology and immunopathology
ISSN: 1873-2534
Titre abrégé: Vet Immunol Immunopathol
Pays: Netherlands
ID NLM: 8002006
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
15
05
2020
revised:
04
08
2020
accepted:
15
10
2020
pubmed:
1
11
2020
medline:
9
7
2021
entrez:
31
10
2020
Statut:
ppublish
Résumé
Aberrant expression of immune check point molecules, programmed death ligand (PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) has been reported in many human cancers with increased protein and gene expression correlated with an aggressive behaviour in some neoplasms. Additionally, PD-L1 blockade has been shown to be an effective therapy for some human cancers. Canine mammary gland tumours have previously been shown to produce PD-L1 protein, but there are no previous studies investigating CTLA-4 in these common canine neoplasms. The present study investigated protein and gene expression of PD-L1 and CTLA-4 using immunohistochemistry and RT-PCR in 41 histologically-malignant, outcome-known CMGTs. The PD-L1 and CTLA-4 immunostaining scores of the mammary gland tumours that subsequently metastasised were significantly higher than those of tumours which did not metastasise (PD-L1: p = 0.005, CTLA-4: p = 0.003). Gene expression of PD-L1 and CTLA-4 was also significantly higher in tumours which subsequently metastasised (PD-L1: p = 0.023, CTLA-4: p = 0.022). Further, higher PD-L1 or CTLA-4 immunostaining scores correlated with shorter survival times of dogs (PD-L1: r
Identifiants
pubmed: 33129194
pii: S0165-2427(20)30168-9
doi: 10.1016/j.vetimm.2020.110142
pii:
doi:
Substances chimiques
B7-H1 Antigen
0
CTLA-4 Antigen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
110142Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.